These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927 [TBL] [Abstract][Full Text] [Related]
23. Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system. Delev D; Heiland DH; Franco P; Reinacher P; Mader I; Staszewski O; Lassmann S; Grau S; Schnell O J Neurooncol; 2019 Jan; 141(1):223-233. PubMed ID: 30467813 [TBL] [Abstract][Full Text] [Related]
24. Cytological features of diffuse and circumscribed gliomas. Esteban-Rodríguez I; López-Muñoz S; Blasco-Santana L; Mejías-Bielsa J; Gordillo CH; Jiménez-Heffernan JA Cytopathology; 2024 Sep; 35(5):534-544. PubMed ID: 37668299 [TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D; Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687 [TBL] [Abstract][Full Text] [Related]
26. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes. Guo H; Kang H; Tong H; Du X; Liu H; Tan Y; Yang Y; Wang S; Zhang W Eur Radiol; 2019 Apr; 29(4):1893-1902. PubMed ID: 30276676 [TBL] [Abstract][Full Text] [Related]
27. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study. Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723 [TBL] [Abstract][Full Text] [Related]
28. Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [ Chen Q; Wang K; Ren X; Zhao X; Chen Q; Fan D; Zhang S; Li X; Ai L J Neurooncol; 2023 Dec; 165(3):547-559. PubMed ID: 38095773 [TBL] [Abstract][Full Text] [Related]
29. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. Macaulay RJ Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765 [TBL] [Abstract][Full Text] [Related]
30. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective? Weller M; Reifenberger G Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376 [TBL] [Abstract][Full Text] [Related]
32. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548 [TBL] [Abstract][Full Text] [Related]
33. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590 [TBL] [Abstract][Full Text] [Related]
34. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis. Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851 [TBL] [Abstract][Full Text] [Related]
35. [Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version]. Malzkorn B; Reifenberger G Pathologe; 2019 Mar; 40(2):131-139. PubMed ID: 30790013 [TBL] [Abstract][Full Text] [Related]
36. MR textural analysis on T Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606 [TBL] [Abstract][Full Text] [Related]
37. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877 [TBL] [Abstract][Full Text] [Related]
38. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma. Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362 [TBL] [Abstract][Full Text] [Related]
39. Ultra-high b-value DWI accurately identifies isocitrate dehydrogenase genotypes and tumor subtypes of adult-type diffuse gliomas. Wang X; Shu X; He P; Cai Y; Geng Y; Hu X; Sun Y; Xiao H; Zheng W; Song Y; Xue Y; Jiang R Eur Radiol; 2024 Oct; 34(10):6751-6762. PubMed ID: 38528135 [TBL] [Abstract][Full Text] [Related]
40. Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline. Halasz LM; Attia A; Bradfield L; Brat DJ; Kirkpatrick JP; Laack NN; Lalani N; Lebow ES; Liu AK; Niemeier HM; Palmer JD; Peters KB; Sheehan J; Thomas RP; Vora SA; Wahl DR; Weiss SE; Yeboa DN; Zhong J; Shih HA Pract Radiat Oncol; 2022; 12(5):370-386. PubMed ID: 35902341 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]